Organogenesis Holding (NASDAQ: ORGO) reported Q2 EPS of ($0.13), $0.14 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $130.2 million versus the consensus estimate of $121.3 million.

GUIDANCE:

Organogenesis Holding sees FY2024 revenue of $445-470 million, versus the consensus of $453.8 million, representing an increase of approximately 3% to 9% year-over-year, as compared to net revenue of $433.1 million for the year ended December 31, 2023.

The 2024 net revenue guidance range assumes:

Net revenue from Advanced Wound Care products between $415.0 million and $435.0 million, an increase of 2% to 7% year-over-year as compared to net revenue of $405.5 million for the year ended December 31, 2023.
Net revenue from Surgical & Sports Medicine products between $30.0 million and $35.0 million, an increase of 9% to 27% year-over-year as compared to net revenue of $27.6 million for the year ended December 31, 2023.

Net loss between $(27.0) million and $(12.0) million and adjusted net income (loss) between $(8.0) million and $7.0 million.
EBITDA between $(17.0) million and $2.0 million and Adjusted EBITDA between $16.0 million and $35.0 million.

For earnings history and earnings-related data on Organogenesis Holding (ORGO) click here.